Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States

Thomas A Albini, J. Bradford Rice, Alan G. White, Michaela Johnson, Julie Reiff, Antonio Flavio Lima, Laura Bartels-Peculis, Gosia Ciepielewska, Winnie W. Nelson

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.

Original languageEnglish (US)
JournalOcular Immunology and Inflammation
DOIs
StatePublished - Jan 1 2019

Fingerprint

Eye Diseases
Economics
Population
Costs and Cost Analysis
Delivery of Health Care
Glaucoma
Cataract
Databases

Keywords

  • economic burden
  • healthcare resource use
  • indirect work loss
  • non-infectious inflammatory eye disease
  • opthalmologic complications

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Cite this

Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States. / Albini, Thomas A; Rice, J. Bradford; White, Alan G.; Johnson, Michaela; Reiff, Julie; Lima, Antonio Flavio; Bartels-Peculis, Laura; Ciepielewska, Gosia; Nelson, Winnie W.

In: Ocular Immunology and Inflammation, 01.01.2019.

Research output: Contribution to journalArticle

Albini, Thomas A ; Rice, J. Bradford ; White, Alan G. ; Johnson, Michaela ; Reiff, Julie ; Lima, Antonio Flavio ; Bartels-Peculis, Laura ; Ciepielewska, Gosia ; Nelson, Winnie W. / Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States. In: Ocular Immunology and Inflammation. 2019.
@article{f0d824bdcbd44f83b597d125c48f9c28,
title = "Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States",
abstract = "Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40{\%}, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46{\%} more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.",
keywords = "economic burden, healthcare resource use, indirect work loss, non-infectious inflammatory eye disease, opthalmologic complications",
author = "Albini, {Thomas A} and Rice, {J. Bradford} and White, {Alan G.} and Michaela Johnson and Julie Reiff and Lima, {Antonio Flavio} and Laura Bartels-Peculis and Gosia Ciepielewska and Nelson, {Winnie W.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/09273948.2018.1560476",
language = "English (US)",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States

AU - Albini, Thomas A

AU - Rice, J. Bradford

AU - White, Alan G.

AU - Johnson, Michaela

AU - Reiff, Julie

AU - Lima, Antonio Flavio

AU - Bartels-Peculis, Laura

AU - Ciepielewska, Gosia

AU - Nelson, Winnie W.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.

AB - Purpose: To assess the economic burden of non-infectious inflammatory eyedisease (NIIED) in a commercially-insured population in the United States Methods: Adult patients with a NIIED diagnosis between 2006 and 2015 were selected from a de-identified, privately insured claims database and were matched 1:1 to a non-NIIED control. Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts. Results: Among the 14 876 matched pairs, NIIED patients were significantly more likely than controls to experience ocular complications, including glaucoma and cataracts (p < 0.001). NIIED patients had significantly higher healthcare resource utilization and costs compared with matched controls (relative difference 40%, p < 0.001). NIIED patients missed 12.2 days of work ($2925 annual work-loss costs), 46% more than non-NIIED patients (p < 0.001). Conclusion: NIIED imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options.

KW - economic burden

KW - healthcare resource use

KW - indirect work loss

KW - non-infectious inflammatory eye disease

KW - opthalmologic complications

UR - http://www.scopus.com/inward/record.url?scp=85062364098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062364098&partnerID=8YFLogxK

U2 - 10.1080/09273948.2018.1560476

DO - 10.1080/09273948.2018.1560476

M3 - Article

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -